University Of California Los Angeles
AACR forum confronts racism, inequality in research
As an oncologist who treats melanoma, Antoni Ribas, MD, PhD, typically views skin color from a strictly scientific perspective.
Trial ‘definitively’ shows superiority of long-acting injectable PrEP
A PrEP regimen containing long-acting injectable cabotegravir provided superior protection against HIV infection compared with daily oral PrEP, updated study findings confirmed.
NIH awards grant to UCLA to develop CAR T-cell therapies for HIV
The NIH awarded a $13.65 million grant to researchers at University of California, Los Angeles, to develop chimeric antigen receptor T-cell therapies for the treatment of HIV.
Palliative care amid COVID-19: ‘Be seen, heard and flexible’
Most discussions about the impact of COVID-19 on cancer care have focused on survival outcomes and whether it is possible to maintain active treatment.
FDA approves immunotherapy regimen for advanced liver cancer
The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Atezolizumab plus bevacizumab improves survival outcomes vs. sorafenib in unresectable HCC
Atezolizumab in combination with bevacizumab improved OS and PFS compared with sorafenib among patients with unresectable hepatocellular carcinoma, according to results of the randomized phase 3 IMbrave150 study published in The New England Journal of Medicine.
Off-the-shelf CAR T-cell therapy effective for advanced T-cell acute lymphoblastic leukemia
TruUCAR GC027 — a gene edited, investigational allogeneic chimeric antigen receptor T-cell therapy — showed efficacy for treatment of relapsed or refractory T-cell acute lymphoblastic leukemia, according to preliminary results of a first-in-human phase 1 study presented at the virtual American Association for Cancer Research Annual Meeting.
Novel CD19/CD22 bispecific CAR-T effective, safe for advanced pediatric ALL
A novel bispecific chimeric antigen receptor T-cell therapy appeared safe and effective for younger patients with relapsed or refractory acute lymphoblastic leukemia, according to the results of a phase 1 dose-escalation study presented at the virtual American Association for Cancer Research Annual Meeting.
Pemetrexed appears safe for maintenance therapy with pembrolizumab in metastatic nonsquamous NSCLC
The addition of pemetrexed plus platinum chemotherapy to the immune checkpoint inhibitor pembrolizumab showed manageable toxicity among patients metastatic nonsquamous non-small cell lung cancer, according to results of a post-hoc analysis of the KEYNOTE-189 trial presented at the virtual American Association for Cancer Research Annual Meeting.